InflaRx N.V.
InflaRx N.V. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies that target the complement system, particularly the C5a/C5aR pathway. The group operates through wholly owned subsidiaries in Germany and the United States, with its principal place of business in Jena, Germany.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueDrug programs designed to inhibit C5a or the C5a receptor in inflammatory disease.
Orally administered small-molecule program under clinical development.
Intravenous anti-C5a monoclonal antibody and related development activity.
Research efforts that support new anti-inflammatory pipeline assets.
Customers
InflaRx does not sell to traditional end-market customers in the way a commercial pharmaceutical company does; its primary counterparties are clinical investigators, trial sites, and eventually healthcare providers and payers if a product is approved. In the development stage, value is created through progression of drug candidates for inflammatory diseases such as hidradenitis suppurativa, AAV, and renal diseases.
Trial sites, investigators, and study vendors that execute izicopan and vilobelimab development programs.
Specialists in immunology, nephrology, and dermatology who would prescribe if products are approved.
Public and private payers that determine reimbursement for approved specialty therapies.
Academic and industry partners that may support discovery, biomarker work, or clinical research.
Strategy
InflaRx’s strategy is centered on building a pipeline around its proprietary anti-C5a and anti-C5aR platform and advancing lead assets through clinical development. The company aims to demonstrate disease-modifying activity in inflammatory disorders where complement biology is relevant and where differentiated mechanisms may support future commercialization.
Clinical success is central to validating the platform and creating future product value.
A differentiated biologic asset can broaden the pipeline and support partnering or commercialization options.
A focused scientific platform can improve target selection and pipeline efficiency.
Geography
InflaRx is headquartered in Jena, Germany, and also maintains offices in Munich and Ann Arbor, Michigan through wholly owned subsidiaries. Its business is organized across Germany and the United States, reflecting a transatlantic development footprint rather than a broad commercial sales network.
Risks
As a clinical-stage biopharmaceutical company, InflaRx depends on successful trial execution, regulatory outcomes, and scientific validation of its complement-focused mechanism. It also faces financing, manufacturing, and commercialization risks typical of drug developers, where delays or negative data can materially affect future prospects.
- Clinical development failureImpact: CriticalLikelihood: Medium
Lead assets depend on positive data from Phase 1/2 studies and later-stage trials.
Exposure: izicopan and vilobelimab programs
- Future funding needsImpact: HighLikelihood: High
Clinical-stage biopharma typically consumes cash before product revenue exists.
Exposure: Ongoing R&D and trial programs
- Regulatory approval riskImpact: HighLikelihood: Medium
Novel anti-inflammatory mechanisms must satisfy safety and efficacy standards.
Exposure: All pipeline candidates
- Competitive scientific landscapeImpact: MediumLikelihood: Medium
Other immunology and inflammation approaches may capture trial sites, partners, or patients.
Exposure: Complement and inflammatory disease targets
Accounting
Judgemental itemsCRO and site costs are often recognized based on estimates before invoices are final.
Impact: Can shift reported research expense between periods
Equity awards are common in biotech and can be a meaningful non-cash cost.
Impact: Affects operating expenses and net loss
The group reports in euros but operates in Germany and the United States.
Impact: Can create volatility in reported results and cash balances
Pipeline assets depend on clinical and regulatory progress for recoverability.
Impact: Could lead to write-downs if programs disappoint
Similar listed companies
Publicly listed companies with a comparable business focus.
Immunic, Inc
IMUX · Pharmaceutical Preparations
Inhibrx Biosciences, Inc.
INBX · Biological Products, (No Diagnostic Substances)
INSMED Inc
INSM · Pharmaceutical Preparations
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Avalo Therapeutics, Inc.
AVTX · Pharmaceutical Preparations
Abivax S.A.
ABVX · Pharmaceutical Preparations
Last updated: 28/09/2026